Auteur A. PIRONA

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Dommages liés à l'usage de drogue en Europe : anciens et nouveaux défis face aux décès évitables et prématurés

I. GIRAUDON ; D. HEDRICH ; A. PIRONA ; A. NOOR ; J. MOUNTENEY | 2018
Dans Swaps (n°88-89, 1er et 2e trimestre 2018) Article : Périodique

FRANÇAIS : Avec au moins 9 100 overdoses, ou décès provoqués par la drogue, en Europe en 2016 - en augmentation de 4% depuis 2015 - la consommation de drogues illicites représente un véritable défi de santé public (EMCDDA European Drug Report 2[...]

Plus d'info

Ajouter à la sélection

Lien externe

Health responses to new psychoactive substances

OEDT = EMCDDA ; A. PIRONA ; A. ATKINSON ; H. SUMNALL | 2016
Rapport

FRANÇAIS : Bien que l'usage de NPS en Europe demeure relativement faible, l'EMCDDA s'alarme des risques liés à la consommation de ces substances. Les données récentes mettent en évidence que les NPS sont à l'origine d'urgences hospitalières et [...]

Plus d'info

Ajouter à la sélection

Lien externe

Documents numériques

Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction

J. STRANG ; T. GROSHKOVA ; A. UCHTENHAGEN ; W. VAN DEN BRINK ; C. HAASEN ; M. T. SCHECHTER ; N. LINTZERIS ; J. BELL ; A. PIRONA ; E. OVIEDO-JOEKES ; R. SIMON ; N. METREBIAN | 2015
Dans British Journal of Psychiatry (Vol.207, n°1, July 2015) Article : Périodique

BACKGROUND: Supervised injectable heroin (SIH) treatment has emerged over the past 15 years as an intensive treatment for entrenched heroin users who have not responded to standard treatments such as oral methadone maintenance treatment (MMT) or[...]

Plus d'info

Ajouter à la sélection

Lien externe

Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons. Results from an EMCDDA trendspotter study

OEDT = EMCDDA ; A. PIRONA ; L. MONTANARI ; I. GIRAUDON ; J. MATIAS ; K. OIEN ; L. VANDAM ; T. SURMONT ; B. GUARITA ; F. MATHIS ; J. MOUNTENEY ; K. NATONIEWSKA ; S. SLEIMAN ; P. GRIFFITHS | 2021
Rapport

Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we live, with European countries having to introduce unprecedented measures to protect public health. As with all areas of life, drug consumption, related harms and dru[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Internet-based drug treatment interventions. Best practice and applications in EU Member States

H. P. TOSSMANN ; LEUSCHENR F. ; R. SIMON ; J. HILLEBRAND ; A. PIRONA | 2009
Rapport

ENGLISH : This report provides a comprehensive review of the relatively new phenomenon of Internet-based drug treatment interventions (DTI). It presents a sample of Internet-based DTI programmes across Europe and outlines their methodologies, [...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Knowledge and utilization of technology-based interventions for substance use disorders: an exploratory study among health professionals in the European Union

G. QUAGLIO ; A. PIRONA ; G. ESPOSITO ; T. KARAPIPERIS ; H. BRAND ; G. DOM ; L. BERTINATO ; L. MONTANARI ; F. KIEFER ; G. CARRA | 2019
Dans Drugs: Education, Prevention and Policy (Vol.26, n°5, October 2019) Article : Périodique

Background: Little is known about the knowledge and use of technology-based interventions (TBIs) by health personnel working in the addiction field across Europe. Methods: An online questionnaire was designed using SurveyMonkey® in order to det[...]

Plus d'info

Ajouter à la sélection

m-Health applications for responding to drug use and associated harms

OEDT = EMCDDA ; M. P. SCHAUB ; J. Y. C. LEE ; A. PIRONA | 2018
Rapport

This paper presents results from a scoping study on the availability of smartphone-based applications in the drugs field within a European and global context. It explores the range of m-health applications available to users and professionals s[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Nouveauté

New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe

A. PIRONA ; A. BO ; D. HEDRICH ; M. FERRI ; N. VAN GELDER ; I. GIRAUDON ; L. MONTANARI ; R. SIMON ; J. MOUNTENEY | 2017
Dans International Journal of Drug Policy (Vol.40, February 2017) Article : Périodique

Background: The availability of new psychoactive substances (NPS) in Europe has rapidly increased over the last decade. Although prevalence levels of NPS use remain low in the general European population, there are serious concerns associated wi[...]

Plus d'info

Ajouter à la sélection

New psychoactive substances in prison. Results from an EMCDDA trendspotter study

OEDT = EMCDDA ; L. VANDAM ; P. BORLE ; L. MONTANARI ; T. SURMONT ; A. PIRONA ; D. HEDRICH ; A. GALLEGOS ; N. SINGLETON ; J. MOUNTENEY ; P. GRIFFITHS | 2018
Rapport

This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large sha[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Nouveauté

Nine reasons why ecstasy is not quite what it used to be

J. MOUNTENEY ; P. GRIFFITHS ; A. BO ; A. CUNNINGHAM ; J. MATIAS ; A. PIRONA | 2018
Dans International Journal of Drug Policy (Vol.51, January 2018) Article : Périodique

This paper explores the recent resurgence in use of ecstasy/MDMA in Europe and highlights keys areas of continuity and divergence between the ecstasy market of the 1990s and the current MDMA market. Based on a scoping study involving a targeted [...]

Plus d'info

Ajouter à la sélection

Recent changes in Europe's MDMA/ecstasy market. Results from an EMCDDA trendspotter study

OEDT = EMCDDA ; J. MOUNTENEY ; A. BO ; A. CUNNINGHAM ; I. GIRAUDON ; J. MATIAS ; A. PIRONA ; N. VAN GELDER ; A. RYBARSKA ; L. VANDAM ; P. GRIFFITHS | 2016
Rapport

This report explores the recent resurgence in use of MDMA in Europe and increased availability of high-strength MDMA tablets, crystals and powders. It notes that the picture is not uniform across European countries, and while overall the region’[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Stimulant use among clients entering drug treatment in Europe

L. MONTANARI ; M. PASINETTI ; B. GUARITA ; L. ROYUELA ; K. MULLIGAN ; J. VICENTE ; D. KLEMPOVA ; A. PIRONA ; A. GYARMATHY | 2013
Dans Drugs: Education, Prevention and Policy (Vol.20, n°1, February 2013) Article : Périodique

The aim of this article is to explore the prevalence of primary illicit stimulant use among people who enter drug treatment in Europe. Drawing on information provided by European Union treatment centres in 2009 (excluding Latvia, Lithuania, Port[...]

Plus d'info

Ajouter à la sélection

Lien externe

The experience of the treatment demand indicator in Europe: A common monitoring tool across 30 countries

L. MONTANARI ; A. PIRONA ; B. GUARITA ; D. HEDRICH ; J. MOUNTENEY ; J. VICENTE | 2019
Dans Journal of Studies on Alcohol and Drugs (Suppl.18, January 2019) Article : Périodique

ENGLISH: OBJECTIVE: The article describes an epidemiological indicator called Treatment Demand Indicator (TDI). The TDI aims to provide professionals and researchers with a common European methodology for collecting and reporting core data on d[...]

Plus d'info

Ajouter à la sélection

The impact of the COVID-19 lockdown on drug service provision in European prisons

L. MONTANARI ; R. TELTZROW ; S. VANMALDEREN ; R. RANIERI ; J. A. MARTIN PELAEZ ; L. VANDAM ; J. MOUNTENEY ; A. PIRONA ; F. MEROUEH ; I. GIRAUDON ; J. MATIAS ; K. SKARUPOVA ; L. ROYUELA ; J. MOREL D'ARLEUX | 2021
Dans International Journal of Prisoner Health (Vol.17, n°3, 2021) Article : Périodique

Purpose: This paper aims to describe the impact of the COVID-19 containment measures on the provision of drug treatment and harm reduction services in European prisons in15 countries during the early phase of the pandemic (March-June 2020). Des[...]

Plus d'info

Ajouter à la sélection

Lien externe

The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans

HUXSTER J. K. ; A. PIRONA ; M. J. MORGAN | 2006
Dans Journal of Psychopharmacology (Vol.20, n°2, 2006) Article : Périodique

All previous studies of the sub-acute effects of ecstasy have failed to adequately control for group differences in psychopathology and past and concurrent substance use. The present study was designed to avoid these limitations. At an initial p[...]

Plus d'info

Ajouter à la sélection